| Modality | Indication | Targets | Stage | Company | Project No. | Detail | |
|---|---|---|---|---|---|---|---|
| 1 | Phase 2 study of Oral VVZ-2471 for the treatment of chronic neuropathic pain | ||||||
| Small molecules | Neuropathic Pain (PHN) | 5-HT2AR, mGluR5 | Phase 2 | Vivozon | RS-2025-25454827 | ||
| 2 | Phase 2a clinical development of Vutiglabridin, a diseasemodifying drug for Parkinson’s disease through PON2-mediated autophagy activation | ||||||
| Small molecules | Parkinson’s disease | Paraoxonase 2 | Phase 2 | Glaceum Inc. | RS-2024-00459662 | ||